The Full Wiki

More info on Vabicaserin

Vabicaserin: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Vabicaserin
Systematic (IUPAC) name
(9aR,12aS)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline
Identifiers
CAS number 620948-34-7
ATC code none
PubChem 11658860
Chemical data
Formula C15H21ClN2 
Mol. mass 264.79 g/mol
Therapeutic considerations
Pregnancy cat.  ?
Legal status Uncontrolled
Routes Oral

Vabicaserin (SCA-136) is a novel antipsychotic and anorectic under development by Wyeth.[1][2] As of 2010 it is in phase II clinical trials for the treatment of psychosis and is in preclinical evaluation for obesity.[1][2][3] It was also under investigation as an antidepressant but this indication appears to have been dropped.[4]

Vabicaserin acts as a selective 5-HT2C receptor full agonist (Ki = 3 nM; EC50 = 8 nM; IA = 100% (relative to 5-HT)) and 5-HT2B receptor antagonist (IC50 = 29 nM).[5][6][7] It is also a very weak antagonist at the 5-HT2A receptor (IC50 = 1,650 nM), though this action is not clinically significant.[5] By activating 5-HT2C receptors, vabicaserin inhibits dopamine release in the mesolimbic pathway, likely underlying its efficacy in alleviating positive symptoms of schizophrenia, and increases acetylcholine and glutamate levels in the prefrontal cortex, suggesting benefits against cognitive symptoms as well.[8][7]

See also

References

  1. ^ a b "Search of: vabicaserin - List Results - ClinicalTrials.gov". http://clinicaltrials.gov/ct2/results?term=vabicaserin. 
  2. ^ a b "Clinical Trial Listings | Wyeth". http://www.wyeth.com/ClinicalTrialListings?query=Schizophrenia. 
  3. ^ "Enzyme Inhibition in Drug Discovery ... - Google Books". http://books.google.com/books?id=GS_98F19H74C&lpg=PA655&dq=vabicaserin&lr=&as_brr=3&pg=PA655#v=onepage&q=&f=false. 
  4. ^ Prof John Kelly (2010). Principles of CNS Drug Development: From Test Tube to Patient. New York: Wiley. ISBN 0-470-51979-7. http://books.google.com/books?id=pfY3xcsu6EsC&lpg=PA266&dq=vabicaserin%20antidepressant&as_brr=3&pg=PA266#v=onepage&q=&f=false. 
  5. ^ a b Rosenzweig-Lipson S, Dunlop J, Marquis KL (November 2007). "5-HT2C receptor agonists as an innovative approach for psychiatric disorders". Drug News & Perspectives 20 (9): 565–71. doi:10.1358/dnp.2007.20.9.1162244. PMID 18176661. http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=3&p_RefId=1162244. 
  6. ^ Tong Z, Chandrasekaran A, Demaio W, et al. (December 2009). "SPECIES DIFFERENCES IN THE FORMATION OF VABICASERIN CARBAMOYL GLUCURONIDE". Drug Metabolism and Disposition: the Biological Fate of Chemicals. doi:10.1124/dmd.109.028639. PMID 20032194. http://dmd.aspetjournals.org/cgi/pmidlookup?view=long&pmid=20032194. 
  7. ^ a b "ECNP-2007 CIS". http://91.142.242.133/07ecnp/index.cfm?fuseaction=CIS2002&hoofdnav=Abstracts&content=abs.details&what=AUTHOR&searchtext=beyer&topicselected=*&selection=ABSTRACT&qryStartRowDetail=1. 
  8. ^ Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge, UK: Cambridge University Press. 2008. ISBN 0-521-85702-3. http://books.google.com/books?id=cWbYxSfKN3cC&lpg=PA447&dq=vabicaserin&lr=&as_brr=3&pg=PA447#v=onepage&q=&f=false. 
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message